Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > PP Closed

<< Previous

Bullboard Posts

Next >>

Comment by rico91on Mar 06, 2021 9:48am

164 Views

Post# 32735836

RE:PP Closed

Surely , Chris, Mark, Dr KSS, Dr Nutt etc. should have enough contacts in the medical community , that they could arrange the sale of shares @ .25 without having to pay $161,400 and issue 645,600 warrants @ .40 that are good for 2 years !!
Does this seem a little ( or alot ) excessive to anyone??
Rico

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China